Skip to main content

Qiagen: Oct 27, 2006

Premium
Qiagen this week released three new RNAi related products.
 
The first is the FlexiPlate siRNA, a line of 96-well plates in 0.1-nmol, 0.25-nmol, and 1-nmol scales for use with human or mouse target genes.
 
SiRNAs and controls, Qiagen said, can be selected and arranged on the plates using a Web-based interface.
 
The company has also released the HP OnGuard siRNA design algorithm.
 
The algorithm incorporates a neural-network algorithm and proprietary homology analysis, in addition to other new features including 3' UTR/seed region analysis, SNP avoidance, and interferon motif avoidance, Qiagen said.
 
Lastly, Qiagen introduced the Human Druggable Genome siRNA set 3.0, which targets more than 7,000 genes of therapeutic value. SiRNAs are available through the set either individually or in pools.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.